Fmr LLC Purchases 4,438,949 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Fmr LLC raised its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 16.3% in the 3rd quarter, Holdings Channel.com reports. The fund owned 31,609,175 shares of the company’s stock after buying an additional 4,438,949 shares during the period. Fmr LLC owned approximately 0.14% of Sana Biotechnology worth $131,494,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Integral Health Asset Management LLC grew its position in Sana Biotechnology by 22.4% in the second quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock valued at $6,552,000 after purchasing an additional 220,000 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Sana Biotechnology by 11.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,047,846 shares of the company’s stock valued at $4,359,000 after acquiring an additional 105,382 shares in the last quarter. Squarepoint Ops LLC increased its position in shares of Sana Biotechnology by 318.8% in the second quarter. Squarepoint Ops LLC now owns 126,572 shares of the company’s stock valued at $691,000 after acquiring an additional 96,348 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Sana Biotechnology by 26.5% during the second quarter. Bank of New York Mellon Corp now owns 431,744 shares of the company’s stock valued at $2,357,000 after purchasing an additional 90,423 shares during the last quarter. Finally, Ensign Peak Advisors Inc bought a new position in Sana Biotechnology in the second quarter valued at approximately $372,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on SANA shares. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Sana Biotechnology in a research note on Wednesday, November 27th. JMP Securities cut shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. Finally, Citigroup boosted their price objective on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, August 9th.

Insider Buying and Selling at Sana Biotechnology

In other news, Director Richard Mulligan sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the transaction, the director now owns 2,848,121 shares of the company’s stock, valued at approximately $11,620,333.68. This represents a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 31.10% of the company’s stock.

Sana Biotechnology Trading Down 9.8 %

Shares of NASDAQ SANA opened at $2.57 on Wednesday. Sana Biotechnology, Inc. has a 12 month low of $2.29 and a 12 month high of $12.00. The stock has a 50 day moving average of $3.48 and a 200-day moving average of $5.04. The company has a market capitalization of $573.80 million, a P/E ratio of -1.84 and a beta of 1.33.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01. Analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.